LLY Options Signal Bullish Momentum: Calls at $1,200 vs. Puts at $1,000 Highlight Breakout Potential

Generated by AI AgentOptions FocusReviewed byShunan Liu
Tuesday, Dec 2, 2025 1:12 pm ET2min read
Aime RobotAime Summary

-

raised Eli Lilly’s price target to $1,286, citing pipeline progress and the Verve acquisition.

- Options data shows heavy call buying at $1,200 (1,039 OI) vs. puts at $1,000 (1,911 OI), signaling bullish bias with downside caution.

- Analysts highlight risks like retatrutide phase 3 results or

competition, which could test $1,000 support levels.

- Aggressive traders target $1,100–$1,200 calls, while cautious strategies include $1,000 puts to hedge against volatility.

  • Bank of America raised Eli Lilly’s price target to $1,286, citing pipeline progress
  • LLY’s $1.06k price sits above all major moving averages, with RSI near overbought levels
  • Options data shows 226k+ call open interest vs. 196k puts, favoring upside

Here’s the thing: LLY’s options market is screaming bullish—but with a twist. While heavy call buying targets a $1,200+ move, the put/call ratio (0.867) and key support levels suggest a cautious setup. Let’s break it down.

What the Options Chain Reveals About Market Sentiment

LLY’s options are a chessboard of bets. This Friday’s top OTM calls are clustered at $1,100–$1,200 (OI: 1,039–1,011), while puts dominate at $1,000–$1,030 (OI: 1,911–1,265). That’s not random—it’s a signal. Heavy call open interest at $1,200 implies big money expects a breakout above current levels, likely fueled by Bank of America’s $1,286 target. But don’t ignore the puts: the $1,000 strike’s 1,911 OI acts like a safety net for bears, hinting at a potential pullback if the stock falters. No block trades to skew the data—this is pure crowd psychology.

News Flow: Pipeline Hype vs. Real-World Risks

Bank of America’s upgrade and the Verve acquisition are huge for LLY’s long-term story. GLP-1 dominance, gene therapy expansion, and orforglipron’s early 2026 launch? That’s a rocket-fuel narrative. But Jim Cramer’s caution rings true: LLY’s valuation hinges on new breakthroughs. If phase 3 results for retatrutide disappoint or Novo Nordisk’s next-gen drugs steal market share, the $1,000 support could crumble. Retail investors are betting on the upside, but institutional hedging via puts suggests they’re bracing for volatility.

Actionable Trades: Calls for the Bold, Puts for the Pragmatic

For the aggressive: Buy

(this Friday’s $1,100 call) or (next Friday’s $1,200 call). Why? The $1,200 strike aligns with Bank of America’s target and Bollinger Upper Band ($1,142). If cracks $1,110–$1,130 resistance (per recent technical analysis), these calls could explode.

For the cautious: Buy

(this Friday’s $1,000 put) or (next Friday’s $1,010 put). These lock in downside protection if the stock dips toward 30D support ($1,016.83–$1,023.04). A risk-reversal strategy (buying the $1,100 call + $1,000 put) could hedge a long position while capping losses.

Stock traders: Consider entry near $1,016.83 (30D support) with a target at $1,110–$1,130. If LLY holds above its 50-day MA ($1,011.72), the bulls control the narrative. A break below $881.37 (Bollinger Lower Band) would be catastrophic—avoid long positions there.

Volatility on the Horizon: Bullish Trends, Pragmatic Prep

LLY’s story is a high-stakes poker game. The options data and news flow both point to a bullish bias, but the RSI (71.2) and MACD histogram (0.097) suggest momentum is slowing. This isn’t a "buy and forget" trade—it’s a "monitor and adapt" scenario. Position size matters: even a small bet on the $1,200 call could pay off if the stock surges, but don’t overcommit. The next two weeks will test whether LLY’s $1 trillion market cap is a milestone or a mirage.

Bottom line: LLY’s options and fundamentals are in sync for a big move. But in this market, even the strongest bulls need a parachute. Stay sharp, stay flexible—and watch that $1,000 support like a hawk.

Comments



Add a public comment...
No comments

No comments yet